EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner

Xiaojing Wang iD, Liangjing Wang, Lin Geng, Naoki Tanaka iD, Bin Ye

International Journal of Molecular Sciences · 19.03.2023 · 24 (6) · 5843

DOI: 10.3390/ijms24065843 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.03.2023. Verfasst von Xiaojing Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Lishui Hospital of Zhejiang University/The Central Hospital of Lishui, Lishui 323000, China. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, RGS Proteins. Die Arbeit wurde bisher 67-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The public welfare technology application research projects from the Science and Technology Bureau of Lishui, Science and Technology Bureau of Lishui.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Resmetirom, a liver-directed, orally active agonist of THR-β, could play a favorable role in treating NASH, but little is known about the underlying mechanism. A NASH cell model was established to test the preventive effect of resmetirom on this disease in vitro. RNA-seq was used for screening, and rescue experiments were performed to validate the target gene of the drug. A NASH mouse model was used to further elucidate the role and the underlying mechanism of resmetirom. Resmetirom effectively eliminated lipid accumulation and decreased triglyceride (TG) levels. In addition, repressed RGS5 in the NASH model could be recovered by resmetirom treatment. The silencing of RGS5 effectively impaired the role of resmetirom. In the NASH mouse model, obvious gray hepatization, liver fibrosis and inflammation, and increased macrophage infiltration were observed in liver tissues, while resmetirom almost returned them to normal conditions as observed in the control group. Pathological experimental data also confirmed that resmetirom has great potential in NASH treatment. Finally, RGS5 expression was suppressed in the NASH mouse model, but it was upregulated by resmetirom treatment, while the STAT3 and NF-κB signaling pathways were activated in NASH but inhibited by the agent. Resmetirom could improve NASH by recovering RGS5 expression and subsequently inactivating the STAT3 and NF-κB signaling pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseRGS ProteinsMiceAnimalsNF-kappa BSignal TransductionLiverMice, Inbred C57BLPyridazinesUracil

Stichwörter der Autor:innen

NASHNF-κBRGS5STAT3resmetirom

Substanzen

NF-kappa BRGS ProteinsresmetiromPyridazinesUracilRgs5 protein, mouse

Autor:innen und Institutionen

  • Department of Gastroenterology, Lishui Hospital of Zhejiang University/The Central Hospital of Lishui, Lishui 323000, China.
  • Department of Gastroenterology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China.
  • Institute of Gastroenterology, Zhejiang University, Hangzhou 310009, China.
  • Department of Global Medical Research Promotion, Shinshu University Graduate School of Medicine, Matsumoto 390-8621, Japan.
  • International Relations Office, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
  • Research Center for Social Systems, Shinshu University, Matsumoto 390-8621, Japan.

ORCID-Profile: Xiaojing Wang, Naoki Tanaka

Förderung

  • The public welfare technology application research projects from the Science and Technology Bureau of Lishui
  • Science and Technology Bureau of Lishui

Zitieren

APA

Wang, X., Wang, L., Geng, L., Tanaka, N., & Ye, B. (2023). Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner. International Journal of Molecular Sciences, 24(6), 5843. https://doi.org/10.3390/ijms24065843

Vancouver

Wang X, Wang L, Geng L, Tanaka N, Ye B. Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner. International Journal of Molecular Sciences. 2023;24(6):5843. doi:10.3390/ijms24065843

BibTeX
@article{Wang2023,
  author = {Wang, Xiaojing and Wang, Liangjing and Geng, Lin and Tanaka, Naoki and Ye, Bin},
  title = {Resmetirom Ameliorates NASH-Model Mice by Suppressing STAT3 and NF-κB Signaling Pathways in an RGS5-Dependent Manner},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {6},
  pages = {5843},
  doi = {10.3390/ijms24065843}
}
Kostenlos starten →